Investors & Media

Dedicated to delivering long-term investment value.

Hero Investors2

At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.

Stock Information

Updated stock ticker information for uniQure

  • NASDAQ:
  • Price:
  • Change:
  • Volume:

(Updated every 15 minutes)

Learn More

SEC Filings

Security and exchange commission filings for uniQure, including quarterly and annual reports

Learn More

Governance

Links to key uniQure corporate governance documents

Learn More

Upcoming Webcasts

No webcasts scheduled. Check back soon.

Webcast Archive

  • AMT-130 Huntington’s Disease Program Update

    View Webcast
  • uniQure AMT-130 Program Update
    8:30 a.m.

    View Webcast
  • Guggenheim Genomic Medicines & Rare Disease Day
    8:00 a.m. ET / 2:00 p.m. CET

    View Webcast
See All

Investor Presentations

  • AMT-130 12-Month Low-Dose Cohort Update – Investor Webcast Presentation

    View Presentation
  • EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B

    View Presentation
  • 2021 Dutch Statutory IFRS Financials

    View Presentation
  • ISTH 2021 – Clinical Outcomes in Adults with Hemophilia B With Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the HOPE-B Trial

    View Presentation
  • Gene Therapy Information

    View Presentation
See All
uniQure Logo Twitter Icon LinkedIn Icon YouTube Icon Twitter Icon Arrow Slideshow Next Button